Chikungunya virus (CHIKV) causes a febrile disease associated with chronic arthralgia, which 52 may progress to neurological impairment. Chikungunya fever (CF) is a consolidated public health problem, 53 in tropical and subtropical regions of the world, where control of CHIKV vector, mosquitos of the Aedes 54 genus, failed. Since there is no vaccine or specific treatment against CHIKV, infected patients receive only 55 palliative care to alleviate pain and arthralgia. Thus, drug repurposing is necessary to identify antivirals 56 against CHIKV. Recently, the structure and activity of CHIKV RNA polymerase was partially resolved, 57 revealing similar aspects with the enzyme counterparner on other positive sense RNA viruses, such as 58 members of the Flaviviridae family. We then evaluated if sofosbuvir, clinically approved against hepatitis C 59 virus RNA polymerase, which also aims to dengue, Zika and yellow fever viruses replication, would inhibit 60 CHIKV replication. Indeed, sofosbuvir was 5-times more selective in inhibiting CHIKV production in 61 human hepatoma cells than ribavirin, a pan-antiviral drug. Although CHIKV replication in human induced 62 pluripotent stem cell (iPS)-derived astrocytes was less sensitive to sofosbuvir's, compared to hepatoma cells 63 this drug still impaired virus production and cell death in a MOI-dependent manner. Sofosbuvir also 64 exhibited antiviral activity in vivo, by preventing CHIKV-induced paw oedeme in adult mice, at 20 65 mg/kg/day, and mortality on neonate mice model, at 40 and 80 mg/kg/day. Our data demonstrates that a 66 prototypic alphavirus, CHIKV, is also susceptible to sofosbuvir. Since this is a clinically approved drug, it 67 could pave the way to become a therapeutic option against CF. 68 69 70 71 72 73 74 75 76 77 78 4 1. Introduction 79 Chikungunya virus (CHIKV) is a member of the Togaviridae family, genus alphavirus, which 80 causes febrile debilitating illness associated with arthralgia and skin rash (1). Although prolonged and 81 debilitating joint pain and oedema differentiate CHIKV infection among contemporary arboviruses, like 82 dengue (DENV) and Zika (ZIKV) viruses, most often these agents display similar clinical signs and 83 symptoms during the early phase of infection (1). Severe outcomes of CHIKV infection, leading to acute 84 and convalescent neurological impairment, have also been described (2, 3). 85 Chikungunya fever (CF) is a consolidated public health problem with substantial impact in tropical 86 and subtropical regions of the world, where Aedes spp mosquitoes are prevalent and control measures failed 87
CHIKV is susceptible to sofosbuvir in vitro 141 To evaluate if sofosbuvir is indeed endowed with anti-CHIKV activity, phenotypic antiviral assays 142 were performed in human cells previously associated to peripheral virus replication and invasion of the 143 nervous system (22), respectively, hepatoma (Huh-7) and astrocytes derived from induced pluripotent stem 144 (iPS) cells. Supernatants from these infected cultures were harvested and tittered in Vero cells. We observed 145 a dose-dependent inhibition of CHIKV production in hepatoma cells ( Figure 2 and Table 2) , which is known 146 to possess the machinery to convert the sofosbuvir prodrug to the pharmacologically active metabolite (12).
147
Sofosbuvir was two-fold more potent and 25 % less cytotoxic than ribavirin (Table 2) . Consequently, 148 selectivity index (SI) for sofosbuvir was almost five-fold better than for ribavirin, a pan-antiviral drug.
149
Moreover, astrocytes succumb to CHIKV infection in a multiplicity of infection (MOI)-dependent manner, 150 and sofosbuvir partially prevented cell mortality ( Figure 3A ). Accordingly, sofosbuvir decreased CHIKV 151 replication on astrocytes by 50 % at MOI of 1 ( Figure 3B ). Sofosbuvir protected CHIKV-infected mice, using models of arthralgia and severe infection. 208 To analyze whether in vitro results translate into a systemic protection, we treated CHIKV-infected 209 mouse with sofosbuvir. Initially, treatment was performed in the arthralgia mouse model, in which 210 sofosbuvir was given orally (20 mg/kg/day) one-hour prior to the injection of 2x10 4 TCID50 into the right 211 rind paw. We observed that early after infection paw oedema did not ameliorate with sofosbuvir, suggesting 212 that this drug had now effect on the swelling associated with the insult caused by the injection ( Figure 4A -213 C). Importantly, in the untreated and infected mice, paw oedema was more intense in the following days,
214
whereas the treated animals displayed no differences to mock-infected mice ( Figure 4D -F and Figure 5 ). (Figure 7) . Importantly, CHIKV-infected and sofosbuvir pre-treated animals did not present 317 neuromotor sequela, meaning that these animals are healthier than infected controls (Figure 7 ). Of note,
318
although the late-treatment diminished the median time associated with neuromotor sequela, some animals 319 displayed a behaviour similar to CHIKV-infected animals, making these groups statistically 320 indistinguishable. Altogether, our data suggests that sofosbuvir also inhibits CHIKV replication in vivo, 321 ameliorating animals' arthralgia, enhancing survival and preserving neuromotor function. 
Discussion

366
CHIKV is among the reemergent arboviruses in the early 21 st century. hepatoma cells. These cells were used because they represent one of the most efficient in vitro models to 390 convert sofosbuvir to the active metabolite and liver is a relevant organ for CHIKV pathogenesis (22, 28) .
391
Growing evidence indicates that CHIKV may impair neurological function, by directly invading the nervous 392 system (28, 34, 35 ExPASy server (44). The region between Met1-Lys516, part of the nsP4 sequence that includes the whole 475 catalytic core was considered to construct the model using I-TASSER server (45). The I-TASSER 476 methodology is very accurate for the construction of protein models when the sequence identity between the 477 target sequence and the template protein drops below 30 %, where lack of a high-quality structure match 478 may provide substantial alignment errors and, consequently, poor quality models (45, 46) . Thus, the final 479 model was validated using two programs: PROCHECK (47) and VERIFY3D (48). PROCHECK analyzes 480 the stereochemical quality and VERIFY3D compatibility analysis between the 3D model and its own amino 481 acid sequence, by assigning a structural class based on its location and environment, and by comparing the 482 results with those of crystal structures with good resolutions (47, 48) . infected and mock-treated groups of animals were used as controls. Animals were monitored daily for 524 survival, weight gain, and virus-induced short-term sequelae (righting in up to 60 seconds).
525
Arthralgia model. Arthralgia model was adapted from previous publications (53, 54) . Male Swiss Webster 526 mice (8 weeks-old; 20-25 g) were infected with 10 4 TCID50 in right hind paw towards the ankle. Sofosbuvir 527 was given orally (20 mg/kg), beginning one-hour before the first virus injection. Treatment was conducted 528 for 6 days. Control group was injected with 50 μL of RPMI. Paw oedema was evaluated from the first to the 529 sixth day after infection by hydropletismometer for small volumes (Ugo Basile, Milan, Italy) and data was 530 presented as paw volume (mL).
531
Behavioural tests. To test the righting reflex, animals were tested daily during the course of acute infection.
532
Animals were held in a supine position with all four paws facing up in the air for 5 seconds. Then, animals 533 were released, and the time the animal took to flip over onto its stomach with all four paws touching the 534 surface was measured. A maximum of 60 seconds was given for each trial, and animals were tested twice a 535 day with a 5-minute minimum interval between trials. For each animal, the lowest time was plotted in the 536 graph. Animals that failed the test were included in the graph with a time of 60 seconds. the Log-rank (Mantel-Cox) test. The equations to fit the best curve were generated based on R 2 values ≥ 0.9.
545
ANOVA, followed by Tukey's post hoc test, tests were also used, with P values <0.05 considered 546 statistically significant. The statistical analyses specific to each software program used in the bioinformatics 547 analysis are described above. 
